SOPHiA GENETICS (SOPH) investor relations material

Platform and differentiation

• SOPHiA DDM launched in 2015; now supports over 1,000 hospitals in more than 70 countries, computing data produced by healthcare providers.

• Core strengths: global network, scalable platform, accurate algorithms, and rapid delivery of new algorithms for heterogeneous data.

• Strategy is expanding beyond genomics to combine multimodal data and follow patients longitudinally; the Executive Chairman is focused on AI, data-generation technologies, and data computation.

Biopharma and data products

• Network spans 75-plus countries and processes more than 400,000 patients annually, supporting CDx, real-world evidence, and other products for biopharma and clinical users.

• A single global platform can help biopharma identify patients across geographies and develop drug-specific algorithms, including predictors for bladder, lung, and prostate cancer.

• AstraZeneca collaborations have covered cohort and therapy data, clinical-trial support, and identifying patients after a drug reaches market; an AI predictor for lung cancer was announced this quarter.

• Biopharma partnerships are positioned as complementary: the value is deploying biomarkers reliably and accurately worldwide, rather than owning the biomarker or doing drug discovery.

U.S. clinical adoption

• U.S. growth exceeded 50% YoY; the U.S. is now the largest market, with management citing improving clinical utility, higher reimbursement, and lower denial rates as adoption drivers.

• In-house testing can generate $2,000-$3,000 in services revenue per patient and, in some cases, more than $1,000 in profit for a hospital or lab after platform costs.

• Recent wins include two of the largest U.S. health systems for enhanced exome; initial verification and validation typically take six to nine months, while adding applications is usually faster.

• MSK-ACCESS liquid biopsy is available at 100 institutions globally; the broader menu spans cancer and rare-disease testing, with transcriptomics and tumor mRNA identified as potential future modalities.

• Revenue visibility into 2027 was 95%, and annual revenue churn was below 1%, reflecting the long ramp and sticky customer relationships.